FDA Class III Atropine Sulfate Ophthalmic Solution Recall for Specification Failures
Somerset Therapeutics is recalling Atropine Sulfate Ophthalmic Solution due to failed impurity and degradation specifications. No illnesses have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class III recall with failed specification tests for impurities and degradation. No illnesses or injuries reported. FDA Class III recalls are typically scored 1 or 2; this is rated 2 because it involves a prescription medication with quality implications, though the source provides no evidence of actual patient harm.
Plain-English summary
Somerset Therapeutics LLC is recalling Atropine Sulfate Ophthalmic Solution, USP 1% (5 mL bottles, Rx only) due to failed impurities and degradation specifications. The affected product is identified by Lot #A240211, with an expiration date of April 2026.
The affected product was distributed nationwide within the United States. Approximately 5,870 bottles were subject to this recall. No illnesses or injuries have been reported in connection with this product.
Healthcare providers and pharmacists who have supplied the recalled product should contact their supplier about obtaining unaffected product. Patients should contact their healthcare provider if they have questions about their medication.
The recalled product
- Product
- ATROPINE SULFATE (ATROPINE SULFATE MONOHYDRATE)
- Brand
- ATROPINE SULFATE
- Manufacturer
- SOMERSET THERAPEUTICS LLC
- Category
- Drug — Ophthalmic
- Hazard
- Affected units
- 5,870
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: A240211
- Exp. Date April 2026
UPCs (1)
- 0370069716014
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ATROPINE SULFATE
- SevereAmerican Regent Recalls Atropine Sulfate Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAtropine Sulfate Injection Recalled for Glass Particulate Matter Contamination
FDA (Drugs) · 2024-01-24
- HighAccord Healthcare Recalls Atropine Sulfate Injection for Particulate Matter Contamination
FDA (Drugs) · 2023-07-19
Same manufacturer · SOMERSET THERAPEUTICS LLC
See all →- HighDexamethasone injection failed impurity specifications at product expiry testing
FDA (Drugs) · 2026-03-25
- ModerateCisatracurium 10 mg vials recalled after subpotent stability assay results
FDA (Drugs) · 2025-12-24
- ModerateCisatracurium 20 mg multiple-dose vials recalled after subpotent assay results
FDA (Drugs) · 2025-12-24
- ModerateCisatracurium 200 mg vials recalled after subpotent stability assay results
FDA (Drugs) · 2025-12-24
- HighHaloperidol Decanoate Injections Recalled for Trace Water Contamination
FDA (Drugs) · 2024-05-29
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17